Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
AstraZeneca
This is a Phase IB, Open-Label, Multi-Center Study to Determine the Efficacy and Safety of Durvalumab and/or Novel Oncology Therapies, With or Without Chemotherapy, for First-Line Stage IV Non-Small Cell Lung Cancer (NSCLC).
Age
18–130
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically documented Stage IV NSCLC not amenable to curative surgery or radiation
No prior chemotherapy or any other systemic therapy for metastatic NSCLC
Prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for advanced disease are eligible, if progression has occurred \>12 months from end of last therapy
Known tumor PD-L1 status
Tumors that lack activating EGFR mutations and ALK fusions or documented local test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care
WHO/ECOG status at 0 or 1 at enrollment
Life expectancy of at least 12 weeks
Troponin I or T ≤ ULN (per institutional guidelines)
You may not be if
Active or prior documented autoimmune or inflammatory disorders
History of active primary immunodeficiency
Any prior chemotherapy or any other systemic therapy for metastatic NSCLC
Untreated CNS metastases
Clareo Health | A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
